Shivalik Rasayan approves preferential allotment of shares and warrants
- Shivalik Rasayan approved preferential allotment of 2,82,000 equity shares and 9,47,990 warrants
- Total capital raised is ₹30.75 crore at an issue price of ₹250 per security
- Promoter entity Growel Remedies received 4,28,000 warrants, the largest single allotment
- Paid-up capital increases to ₹8.01 crore post-equity allotment and ₹8.49 crore on fully diluted basis

*this image is generated using AI for illustrative purposes only.
Shivalik Rasayan approved a preferential allotment of 2,82,000 equity shares and 9,47,990 fully convertible warrants in its board meeting held on September 14, 2026. The transaction raises ₹30.75 crore from promoter and public category investors.
The Board of Directors authorized the issue at a price of ₹250 per security. The equity share allotment targets public investors, while the warrant issuance includes both promoter group entities and public participants.
Equity Share Allotment Details
The company allotted 2,82,000 equity shares with a face value of ₹5 each to five public category allottees. The aggregate amount raised from this tranche is ₹7,05,00,000.
| Name of the Allottee | Category | No. of Equity Shares Allotted |
|---|---|---|
| Harish Pande Jt. Usha Pande | Public | 48,000 |
| Ashwani Kumar Sharma | Public | 1,32,000 |
| Usha Pande Jt. Harish Pande | Public | 42,000 |
| Deepa Pande | Public | 30,000 |
| Jaideep Mahesh Chandra Dwivedi | Public | 30,000 |
| Total | 2,82,000 |
Consequent to this allotment, the paid-up equity share capital increased to ₹8,01,61,825, comprising 1,60,32,365 equity shares.
Warrant Allotment Details
The company also allotted 9,47,990 fully convertible warrants at ₹250 each, raising an aggregate of ₹23,69,97,500. Growel Remedies Limited, classified under the promoter category, received the largest allocation.
| Name of the Allottee | Category | No. of Warrants Allotted |
|---|---|---|
| Growel Remedies Limited | Promoter | 4,28,000 |
| Bishnoi Exports Private Limited | Public | 1,20,000 |
| Ginnerup Capital ApS | Public | 3,99,990 |
| Total | 9,47,990 |
On a fully diluted basis, the paid-up equity share capital will stand at ₹8,49,01,775, comprising 1,69,80,355 equity shares.
What the Numbers Show
The warrant component constitutes approximately 77% of the total capital raised in this transaction. This structure suggests a strategic preference for deferred equity conversion, allowing the company to raise immediate cash while diluting existing shareholders only upon future exercise of the warrants.
Historical Stock Returns for Shivalik Rasayan
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.29% | +15.52% | +41.95% | +27.33% | -23.68% | 0.0% |
What are the specific conversion terms, exercise price, and validity period for the 9.48 lakh fully convertible warrants issued to Growel Remedies and public investors?
How does the ₹30.75 crore raised through this preferential allotment align with Shivalik Rasayan's current capital expenditure plans or debt reduction strategy?
Given that Ginnerup Capital ApS received the largest public warrant allocation, what strategic partnership or market entry opportunities might this imply for Shivalik Rasayan?


































